文献速递浆细胞疾病

多发性骨髓瘤DREAM挑战赛揭示表观遗传调控因子PHF19为侵袭性疾病标志物

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
PubMed 文献 · Leukemia · 2020-02-14

多发性骨髓瘤DREAM挑战赛通过众包方式开发新诊断患者快速进展预测模型,并与已发表模型进行基准比较,发现纳入人口学和临床特征可改进基于基因表达的高风险模型,赛后分析识别出新型表达风险标志物PHF19,一个由年龄、ISS、PHF19和MMSET表达组成的四特征预测器性能与更复杂模型相似。

要点

  • 众包挑战赛开发并基准比较了多发性骨髓瘤快速进展预测模型。
  • 纳入人口学和临床特征可改进基于基因表达的高风险模型。
  • 四特征预测器(年龄、ISS、PHF19和MMSET表达)性能与复杂模型相似。

核心结论

  • 众包挑战赛产生了更稳健的预测器,并识别出PHF19作为新的基于表达的风险标志物。

研究设计与样本

  • 多发性骨髓瘤DREAM挑战赛,众包开发新诊断骨髓瘤患者快速进展预测模型并与已发表模型基准比较。

主要发现

  • 纳入特定人口学和临床特征改进了基于基因表达的高风险模型。
  • 赛后分析识别出新型表达风险标志物PHF19,近期发现其在多发性骨髓瘤中有重要生物学作用。
  • 由年龄、ISS、PHF19和MMSET表达组成的四特征预测器性能与包含更多基因表达特征的复杂模型相似。

临床怎么用

  • 四特征预测器(年龄、ISS、PHF19和MMSET表达)可用于新诊断骨髓瘤患者快速进展风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While the past decade has seen meaningful improvements in clinical outcomes for multiple myeloma patients, a subset of patients does not benefit from current therapeutics for unclear reasons. Many gene expression-based models of risk have been developed, but each model uses a different combination of genes and often involves assaying many genes making them difficult to implement. We organized the Multiple Myeloma DREAM Challenge, a crowdsourced effort to develop models of rapid progression in newly diagnosed myeloma patients and to benchmark these against previously published models. This effort lead to more robust predictors and found that incorporating specific demographic and clinical features improved gene expression-based models of high risk. Furthermore, post-challenge analysis identified a novel expression-based risk marker, PHF19, which has recently been found to have an important biological role in multiple myeloma. Lastly, we show that a simple four feature predictor composed of age, ISS, and expression of PHF19 and MMSET performs similarly to more complex models with many more gene expression features included.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mason MJ, Schinke C, Eng CLP, et al. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020. PMID: 32060406. doi:10.1038/s41375-020-0742-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。